Overall Survival Results with KISQALI® (ribociclib)
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial - The Lancet
Trial Outcome Measures | Download Table
Abbreviations used for outcome measures | Download Scientific Diagram
Overall survival for chemotherapy-treated and-untreated patients with... | Download Scientific Diagram
Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed | Nature Reviews Clinical Oncology
Progression-Free Survival: Meaningful or Simply Measurable? | Journal of Clinical Oncology
Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study - ScienceDirect
JCI Insight - A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia
Survival Analysis
Definition of progression free survival and overall survival for the... | Download Scientific Diagram
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
Outcomes and endpoints in trials of cancer treatment: the past, present, and future - The Lancet Oncology
A joint international consensus statement for measuring quality of survival for patients with childhood cancer | Nature Medicine
Survival in oncology reimbursement decision-making | CMAR
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | NEJM
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM
Standardised survival probabilities: a useful and informative tool for reporting regression models for survival data | British Journal of Cancer
JCI Insight - A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia
Other efficacy outcome measures by allocated treatment. Kaplan-Meier... | Download Scientific Diagram
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe
27 Survival analysis | The Epidemiologist R Handbook
Pulmonary Symptoms Measured by the National Institutes of Health Lung Score Predict Overall Survival, Nonrelapse Mortality, and Patient-Reported Outcomes In Chronic Graft-Versus-Host Disease - Biology of Blood and Marrow Transplantation
Impact of social disparities on 10 year survival rates in paediatric cancers: a cohort study - The Lancet Regional Health – Americas
